









Markets
/
Stocks
/
nasdaq-prph
/

Prophase Labs Inc

PRPH

0.363USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.51MMarket Cap

LossP/E TTM



Prophase Labs Inc

0.363

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Prophase Labs Inc

Currency: USD Updated: 2026-01-02

Key Insights

Prophase Labs Inc's fundamentals are relatively weak, and its growth potential is good.Its valuation is considered fairly valued, ranking 67 out of 78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 16.00.In the medium term, the stock price is expected to trend down.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Prophase Labs Inc's Score

Industry at a Glance

Industry Ranking

67 / 78

Overall Ranking

479 / 4550

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Prophase Labs Inc Highlights

StrengthsRisks

ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.

Growing

The company is in a growing phase, with the latest annual income totaling USD 6.77M.

Overvalued

The company’s latest PE is -0.02, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 303.07K shares, decreasing 50.33% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 53.19K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 4.02.

Analyst Rating

Based on 0 analysts

Current Rating

16.000

Target Price

+5111.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-02

Its latest quarterly revenue reached 883.00K, representing a year-over-year decrease of 71.93%, while its net profit experienced a year-over-year decrease of 3.83%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials

3.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

3.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Prophase Labs Inc's Company Valuation

Currency: USD Updated: 2026-01-02

The current valuation score of Prophase Labs Inc is 7.73, ranking 26 out of 78 in the Healthcare Providers & Services industry. Its current P/E ratio is -0.02, which is -122624.02% below the recent high of 24.99 and -126875.49% above the recent low of -25.90.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/78

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-02

No earnings forecast score is currently available for Prophase Labs Inc. The Healthcare Providers & Services industry's average is 7.54. The average price target is 16.00, with a high of 16.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-02

The current price momentum score of Prophase Labs Inc is 5.89, ranking 65 out of 78 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 0.98 and the support level at -0.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.031

Buy

RSI(14)

51.285

Neutral

STOCH(KDJ)(9,3,3)

31.106

Neutral

ATR(14)

0.153

High Vlolatility

CCI(14)

0.329

Neutral

Williams %R

73.665

Sell

TRIX(12,20)

5.428

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.447

Sell

MA10

0.470

Sell

MA20

0.299

Buy

MA50

0.284

Buy

MA100

0.357

Buy

MA200

0.357

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-02

The latest institutional shareholding proportion is 3.84%, representing a quarter-over-quarter decrease of 47.65%. The largest institutional shareholder is The Vanguard, holding a total of 53.19K shares, representing 0.92% of shares outstanding, with 6.19% decrease in holdings.

Score

Industry at a Glance

Previous score

0.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Karkus (Ted William)

321.53K

Sykon Capital LLC

64.48K

The Vanguard Group, Inc.

Star Investors

53.19K

+30.29%

Susquehanna International Group, LLP

39.79K

+290.03%

Geode Capital Management, L.L.C.

30.29K

+16.93%

Hightower Advisors, LLC

23.73K

+3.44%

Gleckel (Louis)

10.38K

Swisspartners Investment Network AG

5.00K

Two Sigma Investments, LP

4.75K

+25.48%

Risk Assessment

Currency: USD Updated: 2026-01-02

The current risk assessment score of Prophase Labs Inc is 1.55, ranking 71 out of 78 in the Healthcare Providers & Services industry. The company's beta value is -0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.